[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"customer-session":3,"post:klow-peptide-blend":5,"blog-recent":54},{"loggedIn":4},false,{"id":6,"slug":7,"title":8,"content":9,"excerpt":10,"path":11,"modified":12,"featuredImage":13,"seo":18,"date":21,"author":22,"categories":49,"readingMinutes":53},43082,"klow-peptide-blend","KLOW Peptide Blend: GHK-Cu, KPV, BPC-157, and TB-500","\u003Cp>\u003Cstrong>Quick answer:\u003C\u002Fstrong> KLOW is a multi-peptide research blend supplied as a single 80 mg lyophilized vial. It is the generic industry KLOW formulation and combines four components: GHK-Cu, KPV, BPC-157, and TB-500. Read another way, it is the two peptides of the Wolverine Blend (BPC-157 and TB-500) together with the copper tripeptide GHK-Cu and the anti-inflammatory tripeptide KPV. Each component has its own separate research literature. None of the individual components or their combinations are FDA-approved in this formulation, and Velora supplies KLOW for in vitro, ex vivo, and in silico research only.\u003C\u002Fp>\n\u003Ch2>Research use only: what this article is, and what it isn’t\u003C\u002Fh2>\n\u003Cp>This is a compound-education reference on the KLOW research blend. It explains what the four components are and what published research has reported about each. It is not medical advice, not a treatment or self-administration guide, and not a document about any human, veterinary, or cosmetic use.\u003C\u002Fp>\n\u003Cp>None of the components of KLOW is approved by the U.S. Food and Drug Administration in the formulation Velora supplies. Velora Research supplies the blend as research-grade material sold strictly for in vitro, ex vivo, and in silico laboratory research, not for human consumption, veterinary use, in vivo use in any species, or any personal, wellness, nutritional, or cosmetic application. The research described below is drawn from published preclinical and in-vitro studies of each individual component and is reported here for research orientation only. Nothing about the blend or its components is claimed to produce any specific outcome in humans, animals, or therapeutic applications. Researchers are responsible for compliance with applicable law, including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331, § 355, § 360bbb-3), and institutional review requirements.\u003C\u002Fp>\n\u003Ch2>What KLOW is?\u003C\u002Fh2>\n\u003Cp>KLOW is the generic, standard-formulation version of a four-peptide research blend, supplied in a single 80 mg lyophilized vial. Velora does not compound a house-specific version; the vial contains the common industry blend of GHK-Cu, KPV, BPC-157, and TB-500. A useful way to place it is against Velora’s other blends: the GLOW blend is GHK-Cu plus the Wolverine Blend (BPC-157 and TB-500), and KLOW is that same trio with the anti-inflammatory tripeptide KPV added. Co-formulating the four holds their ratio constant so a protocol that calls for all of them can be prepared from one reconstitution.\u003C\u002Fp>\n\u003Ch2>The four components\u003C\u002Fh2>\n\u003Cp>Each component of KLOW comes from a different area of the peptide literature.\u003C\u002Fp>\n\u003Ch3>GHK-Cu\u003C\u002Fh3>\n\u003Cp>GHK-Cu is the copper-bound form of the tripeptide glycyl-L-histidyl-L-lysine. In cell-culture and preclinical models it has been studied across copper-transport chemistry, antioxidant and reactive-oxygen-species pathways, collagen and extracellular-matrix research, and gene-expression profiling of repair-related gene clusters (\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F29986520\u002F\" target=\"_blank\" rel=\"noopener\">Pickart & Margolina, *International Journal of Molecular Sciences*, 2018\u003C\u002Fa>). It is also the reason a blend containing it carries a blue tint and needs protection from light.\u003C\u002Fp>\n\u003Ch3>KPV\u003C\u002Fh3>\n\u003Cp>KPV is a tripeptide, lysine-proline-valine, corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied primarily as an anti-inflammatory peptide, and the biochemistry and preclinical anti-inflammatory effects of alpha-MSH and its C-terminal tripeptide are reviewed in detail by Brzoska and colleagues (\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F18612139\u002F\" target=\"_blank\" rel=\"noopener\">Brzoska et al., *Endocrine Reviews*, 2008\u003C\u002Fa>).\u003C\u002Fp>\n\u003Ch3>BPC-157\u003C\u002Fh3>\n\u003Cp>BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in gastric juice. Published preclinical research has examined it across growth-factor, nitric-oxide, and angiogenesis pathways in animal and in-vitro models (\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F29879879\u002F\" target=\"_blank\" rel=\"noopener\">Sikiric et al., *Current Pharmaceutical Design*, 2018\u003C\u002Fa>).\u003C\u002Fp>\n\u003Ch3>TB-500\u003C\u002Fh3>\n\u003Cp>TB-500 is a synthetic peptide derived from the actin-binding region of thymosin beta-4, characterized in the literature as an actin-modulating peptide associated with cell-migration and angiogenesis research (\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F22074294\u002F\" target=\"_blank\" rel=\"noopener\">Goldstein et al., *Expert Opinion on Biological Therapy*, 2012\u003C\u002Fa>).\u003C\u002Fp>\n\u003Cp>\u003Cstrong>A note on the cited literature.\u003C\u002Fstrong> The references above describe each individual component. They are background on what each molecule is and where it has been studied, not evidence about the behavior of the assembled KLOW blend, which would have to be evaluated on its own. In particular, thymosin beta-4 literature describes the molecular family and is not the same as evidence characterizing a specific commercial TB-500 material.\u003C\u002Fp>\n\u003Ch2>Why the four are combined?\u003C\u002Fh2>\n\u003Cp>KLOW is supplied to support multi-pathway research designs that call for all four components together at a fixed ratio. Co-formulating them holds that ratio constant and removes the variance of reconstituting four separate vials, which reduces one potential source of preparation variability across runs. Because Velora supplies the generic blend rather than a compounded house version, the components are the standard four, and the exact per-component amounts for any vial come from that lot’s Certificate of Analysis.\u003C\u002Fp>\n\u003Ch2>Composition and the COA\u003C\u002Fh2>\n\u003Cp>KLOW is supplied as a single 80 mg lyophilized vial containing GHK-Cu, KPV, BPC-157, and TB-500. Velora states that each component is independently tested by a third-party analytical laboratory, using HPLC for purity and mass spectrometry for identity. Confirm the per-component amounts and ratio for your specific lot against the active COA, which is the primary lot-specific source for reported composition and analytical results.\u003C\u002Fp>\n\u003Ch2>Reconstitution and concentration\u003C\u002Fh2>\n\u003Cp>The information in this section is general laboratory-handling context, not a use protocol. Follow your own institution’s validated standard operating procedures and the product documentation for any specific step.\u003C\u002Fp>\n\u003Cp>KLOW ships as an 80 mg lyophilized vial, reconstituted with bacteriostatic water. Because the per-component split is confirmed on the COA, the table below gives the combined concentration; derive each component’s concentration from the amounts stated on the active COA.\u003C\u002Fp>\n\u003Ctable>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>\u003Cstrong>Diluent volume added\u003C\u002Fstrong>\u003C\u002Ftd>\n\u003Ctd>\u003Cstrong>Combined concentration (mg\u002FmL)\u003C\u002Fstrong>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>4.0 mL\u003C\u002Ftd>\n\u003Ctd>20.0\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>5.0 mL\u003C\u002Ftd>\n\u003Ctd>16.0\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>8.0 mL\u003C\u002Ftd>\n\u003Ctd>10.0\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Cp>As a general handling practice, add the diluent slowly down the inner glass wall and mix by gentle swirling rather than shaking. The four components span a wide size range, from the small GHK-Cu and KPV tripeptides to the larger BPC-157 and TB-500, so per-component molar concentrations differ substantially at any single combined weight. Compute each from its own molecular weight on the COA rather than from the combined figure.\u003C\u002Fp>\n\u003Ch2>Storage\u003C\u002Fh2>\n\u003Cp>Store the lyophilized vial sealed at -20°C in a dry, dark place, and let it equilibrate to room temperature before opening. Protect it from light with particular care, because the GHK-Cu component is documented as light-sensitive. Once reconstituted with bacteriostatic water, refrigerate the working stock at 2 to 8°C, protect it from light, and avoid repeat freeze-thaw cycles, which can degrade peptide integrity. Velora has not published a reconstituted stability window for KLOW, so take the usable timeframe from your protocol and the batch COA. The general logic is in the peptide storage guide.\u003C\u002Fp>\n\u003Cp>\u003Cem>“A four-component blend like this one is where a Certificate of Analysis earns its keep, and I would read the active COA line by line before designing an experiment around KLOW. I want identity by mass spectrometry and purity by HPLC for each component independently, and I pay special attention to the GHK-Cu, because the copper complex is light-sensitive, and its handling shows up in the data. The component literature tells me what each molecule is. The COA tells me what is in the vial in front of me, and at what ratio.”\u003C\u002Fem> \u003Cem>Clark Jones, PhD, Velora Research\u003C\u002Fem>\u003C\u002Fp>\n\u003Ch2>Working with verified material\u003C\u002Fh2>\n\u003Cp>Velora Research supplies the \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct\u002Fklow\u002F\">KLOW peptide blend\u003C\u002Fa> as an 80 mg lyophilized vial, and Velora states each component is independently HPLC- and mass-spec-verified, with a Certificate of Analysis tied to the lot number and published through its \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fcoas\u002F\">Certificates of Analysis\u003C\u002Fa> hub. Those are Velora’s product-specific representations; confirm the specifics for your lot on its COA. The individual peptides also appear elsewhere in the catalog, as \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct\u002Fghk-cu-100mg\u002F\">GHK-Cu\u003C\u002Fa> and the \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct\u002Fwolverine-blend-tb-500-bpc-157-5mg-5mg\u002F\">Wolverine Blend\u003C\u002Fa>, and the same release protocol applies across the full \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct-category\u002Fpeptides\u002F\">research peptide catalog\u003C\u002Fa>. For a multi-component blend, the COA is not a formality; it is how you confirm what you are actually studying.\u003C\u002Fp>\n\u003Ch2>Frequently asked questions\u003C\u002Fh2>\n\u003Ch3>What is the KLOW peptide blend?\u003C\u002Fh3>\n\u003Cp>KLOW is a multi-peptide research blend in a single 80 mg lyophilized vial. It is the generic industry formulation and contains GHK-Cu, KPV, BPC-157, and TB-500. Velora supplies it for in vitro, ex vivo, and in silico research use only.\u003C\u002Fp>\n\u003Ch3>What is in KLOW?\u003C\u002Fh3>\n\u003Cp>Four components: the copper tripeptide GHK-Cu, the anti-inflammatory tripeptide KPV, and BPC-157 plus TB-500 (the two peptides of the Wolverine Blend). Confirm the per-component amounts and ratio for your vial on the active Certificate of Analysis.\u003C\u002Fp>\n\u003Ch3>How does KLOW relate to GLOW?\u003C\u002Fh3>\n\u003Cp>GLOW is GHK-Cu plus BPC-157 and TB-500. KLOW is that same trio with the anti-inflammatory tripeptide KPV added, for a four-component blend.\u003C\u002Fp>\n\u003Ch3>How is the KLOW blend verified?\u003C\u002Fh3>\n\u003Cp>Each component is independently tested by a third-party analytical laboratory using HPLC for purity and mass spectrometry for identity, with a Certificate of Analysis tied to the lot number.\u003C\u002Fp>\n\u003Ch3>Is KLOW FDA-approved?\u003C\u002Fh3>\n\u003Cp>No. None of the components is approved by the FDA in this formulation. KLOW is research-grade material for in vitro, ex vivo, and in silico laboratory use only, not for human or veterinary use.\u003C\u002Fp>\n\u003Ch2>Sources and further reading\u003C\u002Fh2>\n\u003Cul>\n\u003Cli>Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. \u003Cem>International Journal of Molecular Sciences\u003C\u002Fem>. 2018;19(7):1987. \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F29986520\u002F\" target=\"_blank\" rel=\"noopener\">PubMed\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. \u003Cem>Endocrine Reviews\u003C\u002Fem>. 2008;29(5):581-602. \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F18612139\u002F\" target=\"_blank\" rel=\"noopener\">PubMed\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. \u003Cem>Current Pharmaceutical Design\u003C\u002Fem>. 2018;24(18):1990-2001. \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F29879879\u002F\" target=\"_blank\" rel=\"noopener\">PubMed\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. \u003Cem>Expert Opinion on Biological Therapy\u003C\u002Fem>. 2012;12(1):37-51. \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F22074294\u002F\" target=\"_blank\" rel=\"noopener\">PubMed\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Ch2>About the author\u003C\u002Fh2>\n\u003Cp>Clark Jones, PhD is a pharmaceutical scientist and medical writer with expertise in molecular biology, oncology, and chemistry. He has worked in the fields of oncology research, regenerative medicine, and pharmaceutical quality control. He has extensive experience with peptide formulations and development in research. In his work, he translates complex scientific literature into evidence-based content while maintaining regulatory and scientific integrity.\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Forcid.org\u002F0009-0005-9356-0297\" target=\"_blank\" rel=\"noopener\">ORCID 0009-0005-9356-0297\u003C\u002Fa> · \u003Ca href=\"https:\u002F\u002Fwww.linkedin.com\u002Fin\u002Fclark-jones-phd-a0042112\" target=\"_blank\" rel=\"noopener\">LinkedIn\u003C\u002Fa> · More articles by Clark Jones\u003Cbr \u002F>\n\u003Cscript type=\"application\u002Fld+json\">\n{\n  \"@context\": \"https:\u002F\u002Fschema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the KLOW peptide blend?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"KLOW is a multi-peptide research blend supplied in a single 80 mg lyophilized vial. It contains GHK-Cu, KPV, BPC-157, and TB-500 and is supplied for in vitro, ex vivo, and in silico research use only.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is in KLOW?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"KLOW contains four components: the copper tripeptide GHK-Cu, the tripeptide KPV, BPC-157, and TB-500. Confirm the per-component amounts and ratio for your vial using the active Certificate of Analysis.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How does KLOW relate to GLOW?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"GLOW contains GHK-Cu, BPC-157, and TB-500. KLOW contains those same three components plus the tripeptide KPV, making it a four-component blend.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How is the KLOW blend verified?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Each component is independently tested by a third-party analytical laboratory using HPLC for purity and mass spectrometry for identity. A Certificate of Analysis is provided and tied to the applicable lot number.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is KLOW FDA-approved?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"No. KLOW is not FDA-approved, and its components are not approved by the FDA in this formulation. It is research-grade material intended only for in vitro, ex vivo, and in silico laboratory research, not for human or veterinary use.\"\n      }\n    }\n  ]\n}\n\u003C\u002Fscript>\u003C\u002Fp>\n","Quick answer: KLOW is a multi-peptide research blend supplied as a single 80 mg lyophilized vial. It is the generic industry KLOW formulation and combines four components: GHK-Cu, KPV, BPC-157, and…","\u002Fblogs\u002Fklow-peptide-blend","2026-10-14T10:41:10",{"src":14,"alt":15,"width":16,"height":17},"https:\u002F\u002Fwp.veloraresearch.com\u002Fwp-content\u002Fuploads\u002F2026\u002F09\u002FKLOW-Peptide-Blend.jpg","KLOW Peptide Blend",1376,768,{"title":19,"description":20,"canonical":19,"ogTitle":19,"ogDescription":20,"ogImage":14,"robots":19},null,"Explore the KLOW peptide blend featuring GHK-Cu, KPV, BPC-157, and TB-500, including what they are, how they work, and key considerations before use.","2026-09-22T10:46:13",{"id":23,"slug":24,"name":25,"firstName":25,"display":26,"credentials":27,"bio":28,"avatar":29,"avatar2x":30,"roles":31,"focusAreas":34,"expertise":39,"orcid":45,"linkedin":46,"editorialNote":47,"path":48},33,"clarkjones","Clark Jones","Clark Jones, PhD","PhD","Clark Jones, PhD is a pharmaceutical scientist and medical writer with expertise in molecular biology, oncology, and chemistry. He has worked in the fields of oncology research, regenerative medicine, and pharmaceutical quality control, and holds extensive experience with peptide formulations and development in research.\r\n\r\nIn his work, he translates complex scientific literature into evidence-based content while maintaining regulatory and scientific integrity. Every article he writes for Velora Research is grounded in primary sources and framed for a research audience.","https:\u002F\u002Fwp.veloraresearch.com\u002Fwp-content\u002Fuploads\u002F2026\u002F07\u002Fclark-jones-headshot-100x100.jpg","https:\u002F\u002Fwp.veloraresearch.com\u002Fwp-content\u002Fuploads\u002F2026\u002F07\u002Fclark-jones-headshot-300x300.jpg",[32,33],"Pharmaceutical Scientist","Medical Writer",[35,36,37,38],"Molecular Biology","Oncology","Chemistry","Peptide Development",[40,41,37,42,43,44],"Molecular biology","Oncology research","Regenerative medicine","Pharmaceutical quality control","Peptide formulation & development","https:\u002F\u002Forcid.org\u002F0009-0005-9356-0297","https:\u002F\u002Fwww.linkedin.com\u002Fin\u002Fclark-jones-phd-a0042112","Content authored for Velora Research is intended for educational and laboratory research purposes only. It is not medical advice and does not describe use in humans.","\u002Fauthor\u002Fclarkjones",[50],{"name":51,"slug":52},"Blogs","blogs",7,{"posts":55,"total":139,"totalPages":140},[56,79,98,118],{"id":57,"slug":58,"title":59,"content":60,"excerpt":61,"path":62,"modified":63,"featuredImage":64,"seo":68,"date":71,"author":72,"categories":76,"readingMinutes":78},43549,"semax-peptide","Semax Peptide: Mechanism, Research Areas, and Reconstitution Reference","\u003Cp>\u003Cstrong>Quick answer:\u003C\u002Fstrong>\u003Cspan style=\"font-weight: 400;\"> Semax is a synthetic seven-amino-acid peptide derived from a short fragment of adrenocorticotropic hormone (ACTH), with a C-terminal Pro-Gly-Pro extension (stabilizing tail) that increases resistance to enzymatic degradation. The published research characterizes it mostly in brain-derived neurotrophic factor (BDNF) signaling and cerebrovascular models, and it is one of the most heavily studied compounds in the Russian neuropeptide literature. It is an approved clinical drug in Russia, but it is not approved anywhere in the West, and Velora supplies it strictly as a research compound.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>Research use only: what this article is, and what it isn’t\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">This article is a research reference for scientists evaluating Semax for in-vitro or preclinical work. It is not medical advice, and it is not a guide to human use.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Semax is not approved by the U.S. Food and Drug Administration, the European Medicines Agency, or any other Western regulator for any therapeutic indication. It is approved as a clinical pharmaceutical in Russia under regional regulators and is marketed there in a 0.1% intranasal formulation, but that regional clinical product is not the same thing as a research-grade peptide. The Semax that Velora Research supplies is a lyophilized research compound sold strictly for laboratory research use, not for human consumption, veterinary use, or any personal, nutritional, or cosmetic application.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Every effect described below comes from published preclinical or clinical literature and is framed as an observation in a research model, not a benefit to a person. Researchers are responsible for compliance with all applicable law, including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331, § 355, § 360bbb-3), and institutional review requirements.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>What Semax actually is\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The sequence tells the story. Semax is a heptapeptide, derived from the ACTH (4-10) region consisting of the ACTH (4-7) pharmacophore with a C-terminal Pro-Gly-Pro extension, Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH fragment, a short piece of adrenocorticotropic hormone that lacks the hormonal activity of the full molecule but retains signaling behavior in the nervous system. The last three residues, Pro-Gly-Pro, are a stabilizing extension that slows enzymatic degradation, the same design choice used in its sister peptide Selank.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Semax was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its molecular weight is approximately 813.93 g\u002Fmol, with the molecular formula C37H51N9O10S and CAS number 80714-61-0. In the literature it is sometimes written simply as MEHFPGP, its single-letter sequence.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The important conceptual point is that Semax is a fragment analog: it borrows a piece of a hormone, drops the hormonal function, and keeps a regulatory signaling role that the research has characterized largely in neurotrophic and cerebrovascular models.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>What has the research actually shown?\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The Semax evidence base most consistently implicates modulation of the BDNF signaling pathway. BDNF is a protein that supports neuron growth, survival, and synaptic plasticity.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>BDNF and trkB in the hippocampus.\u003C\u002Fstrong>\u003Cspan style=\"font-weight: 400;\"> In rats, a single intranasal application of Semax was shown to regulate BDNF and trkB expression in the hippocampus, and the authors connected this to the peptide’s documented effects on learning (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F16996037\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">Dolotov et al., *Brain Research*, 2006\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">). trkB is the receptor BDNF binds to, so a compound that affects both the ligand and its receptor is doing something coordinated rather than incidental.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>BDNF protein in the basal forebrain.\u003C\u002Fstrong>\u003Cspan style=\"font-weight: 400;\"> A companion study reported that Semax binds specifically in the rat basal forebrain and increases BDNF protein levels there, offering a molecular clue to the neurotrophic activity seen across the behavioral work (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F16635254\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">Dolotov et al., *Journal of Neurochemistry*, 2006\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">). Taken together, the two 2006 papers give a reasonably specific mechanistic picture: Semax influences the BDNF system at both the protein and expression levels in these rat models.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Neurotrophins after cerebral ischemia.\u003C\u002Fstrong>\u003Cspan style=\"font-weight: 400;\"> In a rat model of cerebral ischemia, Semax and its C-terminal Pro-Gly-Pro fragment were shown to activate the transcription of neurotrophins and their receptor genes, including BDNF, NGF, and TrkB (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F19633950\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">Dmitrieva et al., *Cellular and Molecular Neurobiology*, 2010\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">). This cerebrovascular line of research is a large part of why Semax is so heavily represented in the Russian stroke literature.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Human neuroimaging.\u003C\u002Fstrong>\u003Cspan style=\"font-weight: 400;\"> As with Selank, one of the few published human neuroimaging studies used resting-state functional MRI to examine how Semax affects whole-brain functional connectivity in 52 healthy participants (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32342318\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">Panikratova et al., *Doklady Biological Sciences*, 2020\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">). It is a useful anchor precisely because so much of the rest of the Semax evidence base is animal work.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">If you are designing a study, the pattern is clear: the most consistently reported mechanistic finding is the BDNF signal and neurotrophic-factor mechanism, the cerebrovascular models are the second major cluster, and the direct human evidence remains limited relative to the volume of preclinical work.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>Semax at a glance\u003C\u002Fh2>\n\u003Cdiv style=\"max-width: 100%; overflow-x: auto; margin: 24px 0; border-radius: 16px; box-shadow: 0 12px 30px rgba(15, 23, 42, 0.08); border: 1px solid #e2e8f0; background: #ffffff;\">\n\u003Ctable style=\"width: 100%; min-width: 600px; border-collapse: separate; border-spacing: 0; font-family: Arial, Helvetica, sans-serif; font-size: 15px; line-height: 1.7; color: #334155;\">\n\u003Cthead>\n\u003Ctr style=\"background: #111827; color: #ffffff;\">\n\u003Cth style=\"width: 30%; padding: 17px 20px; text-align: left; font-size: 14px; font-weight: bold; letter-spacing: 0.3px; border-bottom: 3px solid #3b82f6;\">Attribute\u003C\u002Fth>\n\u003Cth style=\"padding: 17px 20px; text-align: left; font-size: 14px; font-weight: bold; letter-spacing: 0.3px; border-bottom: 3px solid #3b82f6;\">Details\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr style=\"background: #f8fafc;\">\n\u003Ctd style=\"padding: 15px 20px; font-weight: bold; color: #0f172a; border-bottom: 1px solid #e2e8f0;\">Sequence\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 20px; border-bottom: 1px solid #e2e8f0;\">Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr style=\"background: #ffffff;\">\n\u003Ctd style=\"padding: 15px 20px; font-weight: bold; color: #0f172a; border-bottom: 1px solid #e2e8f0;\">Class\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 20px; border-bottom: 1px solid #e2e8f0;\">Synthetic heptapeptide; ACTH (4–7) fragment analog\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr style=\"background: #f8fafc;\">\n\u003Ctd style=\"padding: 15px 20px; font-weight: bold; color: #0f172a; border-bottom: 1px solid #e2e8f0;\">Molecular Weight\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 20px; border-bottom: 1px solid #e2e8f0;\">Approximately 813.93 g\u002Fmol (per Velora product specifications)\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr style=\"background: #ffffff;\">\n\u003Ctd style=\"padding: 15px 20px; font-weight: bold; color: #0f172a; border-bottom: 1px solid #e2e8f0;\">Molecular Formula\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 20px; border-bottom: 1px solid #e2e8f0;\">C\u003Csub>37\u003C\u002Fsub>H\u003Csub>51\u003C\u002Fsub>N\u003Csub>9\u003C\u002Fsub>O\u003Csub>10\u003C\u002Fsub>S\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr style=\"background: #f8fafc;\">\n\u003Ctd style=\"padding: 15px 20px; font-weight: bold; color: #0f172a; border-bottom: 1px solid #e2e8f0;\">CAS Number\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 20px; border-bottom: 1px solid #e2e8f0;\">80714-61-0\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr style=\"background: #ffffff;\">\n\u003Ctd style=\"padding: 15px 20px; font-weight: bold; color: #0f172a; border-bottom: 1px solid #e2e8f0;\">Origin\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 20px; border-bottom: 1px solid #e2e8f0;\">Institute of Molecular Genetics, Russia, 1980s\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr style=\"background: #f8fafc;\">\n\u003Ctd style=\"padding: 15px 20px; font-weight: bold; color: #0f172a; border-bottom: 1px solid #e2e8f0;\">Primary Research Areas\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 20px; border-bottom: 1px solid #e2e8f0;\">BDNF and neurotrophic research, cerebrovascular models, cognitive models, dopaminergic signaling, and melanocortin signaling\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr style=\"background: #ffffff;\">\n\u003Ctd style=\"padding: 15px 20px; font-weight: bold; color: #0f172a;\">Regulatory Status (Russia)\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 20px;\">Reported as an approved prescription medication in Russia under the Semax brand (0.1% intranasal formulation); verify current status against official regulatory sources.\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003C\u002Fdiv>\n\u003Ch2>Reconstitution and concentration, in the units that matter\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">For a 10 mg vial, a common laboratory starting point is 2 mL of bacteriostatic water, giving a 5 mg\u002FmL stock. Using Velora’s product-page molecular weight of 813.93 g\u002Fmol, that 5 mg\u002FmL stock corresponds to approximately 6.14 mM. Cell-based assays that need nanomolar-to-micromolar working concentrations will require serial dilution in an assay-appropriate buffer; a 6.14 mM stock diluted 1:1,000 lands at roughly 6.14 µM.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The technique is the same as for any lyophilized peptide: add diluent slowly against the inner glass wall, swirl gently, and label the vial with the date and the final concentration in both mg\u002FmL and mM. Confirm the molecular weight on your specific batch Certificate of Analysis before finalizing the molar math, because that number drives every downstream dilution.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">For storage, follow standard peptide-chemistry practice: keep the lyophilized vial sealed at -20°C, protected from light, and refrigerate any reconstituted stock at 2 to 8°C. Velora has not published a specific reconstituted stability window for this product, so treat the usable timeframe as something to establish from your own protocol and the batch COA rather than a fixed shelf life.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>Routes used in published research\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Two administration routes dominate the published Semax research in animal models: intranasal and subcutaneous. The intranasal route is the one used throughout much of the Russian literature, which is also why “semax nasal spray” is such a common search term. For research purposes, the route in any protocol is a study-design decision to be selected and validated against the peer-reviewed literature and institutional approvals. None of these routes is a translation to human or veterinary use, and the Velora product is not sold for any such purpose.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>Semax and Selank: the sister-peptide question\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Semax and Selank get studied side by side so often that it is worth stating the difference plainly. Both are seven-amino-acid regulatory peptides from the same Russian institute, both carry the C-terminal Pro-Gly-Pro stabilization, and both are approved clinical drugs in Russia while remaining research-only in the West. The difference is origin and research focus. Semax descends from an ACTH (4-7) fragment and is most studied in BDNF, neurotrophic-factor, and cerebrovascular research. Selank descends from tuftsin and is most studied in anxiolytic and GABA-system research. For the full treatment of the other peptide, see our Selank research reference.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cblockquote>\u003Cp>\u003Cspan style=\"font-weight: 400;\">“The thing I find genuinely interesting about Semax from a chemistry standpoint is how tidy the mechanism story is. Two independent 2006 papers put the BDNF signal at both the protein and the expression level in the same animal models. That kind of convergence is rare, and it is exactly the sort of claim I want verified against the primary source rather than repeated secondhand. The COA on the vial is the other half of that discipline.”\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Clark Jones, PhD, Velora Research\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fblockquote>\n\u003Ch2>Working with verified material\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Velora Research supplies \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct\u002Fsemax-10mg\u002F\">\u003Cspan style=\"font-weight: 400;\">Semax peptide as a 10 mg lyophilized research compound\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\"> with a batch-specific third-party Certificate of Analysis. Each COA confirms identity by mass spectrometry and purity by HPLC at ≥99%, tied to the lot number on the vial. The same release protocol applies across the \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct-category\u002Fpeptides\u002F\">\u003Cspan style=\"font-weight: 400;\">research peptide catalog\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">, and the \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fabout-us\u002F\">\u003Cspan style=\"font-weight: 400;\">quality and testing process\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\"> is documented end to end. For a compound whose research value rests on a specific sequence and a specific mechanism, confirming identity and purity before the peptide enters a study is not optional.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>Frequently asked questions\u003C\u002Fh2>\n\u003Ch3>What is Semax used for in research?\u003C\u002Fh3>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Published preclinical and clinical literature has characterized Semax across several research areas: BDNF and neurotrophic-factor expression, cerebrovascular and ischemia models, cognitive-behavior assays, and dopaminergic and melanocortin-receptor signaling. These are areas of published research interest observed in experimental systems. They are not therapeutic claims and do not describe outcomes in people.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch3>Is Semax FDA-approved?\u003C\u002Fh3>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">No. Semax is not approved by the FDA or the EMA for any indication. It is approved as a prescription medication in Russia, but that regional product is distinct from a research-grade peptide, and Velora’s Semax is supplied strictly for laboratory research.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch3>What is Semax’s molecular weight?\u003C\u002Fh3>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Approximately 813.93 g\u002Fmol, with the formula C37H51N9O10S, per Velora’s product specifications. Confirm the value on your batch COA before calculating molar concentrations.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch3>How does Semax differ from Selank?\u003C\u002Fh3>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Both are seven-amino-acid Russian-developed regulatory peptides sharing the Pro-Gly-Pro stabilization. Semax comes from an ACTH(4-7) fragment and is most studied in BDNF and cerebrovascular research; Selank comes from tuftsin and is most studied in anxiolytic and GABA-system research.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch3>What is the sequence of Semax?\u003C\u002Fh3>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). The first four residues are the ACTH (4-7) fragment; the last three are a stabilizing extension.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>Sources and further reading\u003C\u002Fh2>\n\u003Cul>\n\u003Cli style=\"font-weight: 400;\">\u003Cspan style=\"font-weight: 400;\">Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH (4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. \u003C\u002Fspan>\u003Cem>\u003Cspan style=\"font-weight: 400;\">Brain Research\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"font-weight: 400;\">. 2006;1117(1):54-60. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F16996037\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">PubMed\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\">\u003Cspan style=\"font-weight: 400;\">Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. \u003C\u002Fspan>\u003Cem>\u003Cspan style=\"font-weight: 400;\">Journal of Neurochemistry\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"font-weight: 400;\">. 2006;97 Suppl 1:82-86. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F16635254\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">PubMed\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\">\u003Cspan style=\"font-weight: 400;\">Dmitrieva VG, Povarova OV, Skvortsova VI, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. \u003C\u002Fspan>\u003Cem>\u003Cspan style=\"font-weight: 400;\">Cellular and Molecular Neurobiology\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"font-weight: 400;\">. 2010;30(1):71-79. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F19633950\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">PubMed\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\">\u003Cspan style=\"font-weight: 400;\">Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. \u003C\u002Fspan>\u003Cem>\u003Cspan style=\"font-weight: 400;\">Doklady Biological Sciences\u003C\u002Fspan>\u003C\u002Fem>\u003Cspan style=\"font-weight: 400;\">. 2020;490(1):9-11. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32342318\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">PubMed\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Ch2>About the author\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Clark Jones, PhD is a pharmaceutical scientist and medical writer with expertise in molecular biology, oncology, and chemistry. He has worked in the fields of oncology research, regenerative medicine, and pharmaceutical quality control. He has extensive experience with peptide formulations and development in research. In his work, he translates complex scientific literature into evidence-based content while maintaining regulatory and scientific integrity.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Forcid.org\u002F0009-0005-9356-0297\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">ORCID 0009-0005-9356-0297\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\"> · \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.linkedin.com\u002Fin\u002Fclark-jones-phd-a0042112\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">LinkedIn\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\"> · More articles by Clark Jones\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cspan style=\"font-weight: 400;\">This article is provided for laboratory and scientific reference. Semax is a research compound, not an approved drug in the United States or European Union. The research-grade material Velora Research supplies is distinct from the Semax-brand pharmaceutical approved by regulators in Russia. Products sold by Velora Research are for in-vitro research use only and are not intended for human or veterinary use. Researchers are responsible for compliance with applicable laws and institutional protocols.\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cscript type=\"application\u002Fld+json\">\n{\n  \"@context\": \"https:\u002F\u002Fschema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Semax used for in research?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Published preclinical and clinical literature has characterized Semax across several research areas, including BDNF and neurotrophic-factor expression, cerebrovascular and ischemia models, cognitive-behavior assays, and dopaminergic and melanocortin-receptor signaling. These are areas of published research interest observed in experimental systems. They are not therapeutic claims and do not describe outcomes in people.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Semax FDA-approved?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"No. Semax is not approved by the FDA or the EMA for any indication. It is approved as a prescription medication in Russia, but that regional product is distinct from a research-grade peptide, and Velora's Semax is supplied strictly for laboratory research.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Semax's molecular weight?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Semax has an approximate molecular weight of 813.93 g\u002Fmol, with the molecular formula C37H51N9O10S, according to Velora's product specifications. Confirm the value on your batch certificate of analysis (COA) before calculating molar concentrations.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How does Semax differ from Selank?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Both are seven-amino-acid Russian-developed regulatory peptides sharing the Pro-Gly-Pro stabilization. Semax comes from an ACTH(4-7) fragment and is most studied in BDNF and cerebrovascular research, while Selank comes from tuftsin and is most studied in anxiolytic and GABA-system research.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the sequence of Semax?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"The amino acid sequence of Semax is Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). The first four residues are the ACTH (4-7) fragment, while the last three form a stabilizing extension.\"\n      }\n    }\n  ]\n}\n\u003C\u002Fscript>\u003C\u002Fp>\n","Quick answer: Semax is a synthetic seven-amino-acid peptide derived from a short fragment of adrenocorticotropic hormone (ACTH), with a C-terminal Pro-Gly-Pro extension (stabilizing tail) that…","\u002Fblogs\u002Fsemax-peptide","2026-10-16T05:10:45",{"src":65,"alt":59,"width":66,"height":67},"https:\u002F\u002Fwp.veloraresearch.com\u002Fwp-content\u002Fuploads\u002F2026\u002F10\u002FSemax-Peptide_-Mechanism-Research-Areas-and-Reconstitution-Reference-1.jpg",1800,1000,{"title":69,"description":70,"canonical":19,"ogTitle":69,"ogDescription":70,"ogImage":65,"robots":19},"Semax Peptide Research: Mechanism and Key Findings","Understand Semax peptide, its mechanism of action, published research areas, and important considerations for research-focused reconstitution references.","2026-10-15T05:09:34",{"id":23,"slug":24,"name":25,"firstName":25,"display":26,"credentials":27,"bio":28,"avatar":29,"avatar2x":30,"roles":73,"focusAreas":74,"expertise":75,"orcid":45,"linkedin":46,"editorialNote":47,"path":48},[32,33],[35,36,37,38],[40,41,37,42,43,44],[77],{"name":51,"slug":52},8,{"id":80,"slug":81,"title":82,"content":83,"excerpt":84,"path":85,"modified":86,"featuredImage":87,"seo":90,"date":92,"author":93,"categories":97,"readingMinutes":78},43526,"selank-peptide-mechanism-research-reconstitution","Selank Peptide: Mechanism, Research Areas, and Reconstitution Reference","\u003Cp>\u003Cstrong>Quick answer:\u003C\u002Fstrong> Selank is a synthetic seven-amino-acid peptide built from the natural immunomodulatory tetrapeptide tuftsin, with a stabilizing tail added so it survives longer in solution. Most of the published research characterizes it in anxiety and GABA-system models, largely from Russian and Eastern European groups. It is approved as a prescription medication for certain neurological and anxiety-related indications in Russia and Ukraine, but in the United States and the EU it is not approved for any use, and Velora supplies it strictly as a research compound.\u003C\u002Fp>\n\u003Ch2>Research use only: what this article is, and what it isn’t\u003C\u002Fh2>\n\u003Cp>This article is a research-oriented reference for scientists evaluating Selank for in-vitro or preclinical work. It is not medical advice, and it is not a guide to human use.\u003C\u002Fp>\n\u003Cp>Selank is not approved by the U.S. Food and Drug Administration, the European Medicines Agency, or any other Western regulator for any therapeutic indication. It is approved as a clinical pharmaceutical in Russia and Ukraine under regional regulators, including for generalized anxiety disorder, but that regional clinical product is a different thing from a research-grade peptide. The Selank that Velora Research supplies is a lyophilized research compound sold strictly for laboratory research use, not for human consumption, veterinary use, or any personal, nutritional, or cosmetic application.\u003C\u002Fp>\n\u003Cp>Every effect described below is drawn from published preclinical or clinical literature and is framed as an observation in a research model, not a benefit to a person. Researchers are responsible for compliance with all applicable law, including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331, § 355, § 360bbb-3), and institutional review requirements.\u003C\u002Fp>\n\u003Ch2>What Selank actually is?\u003C\u002Fh2>\n\u003Cp>Start with the sequence, because it explains almost everything about the molecule. Selank is a heptapeptide (seven amino acids) with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues, Thr-Lys-Pro-Arg, are tuftsin, a naturally occurring tetrapeptide first identified as an immune-modulating fragment of the antibody heavy chain. The last three residues, Pro-Gly-Pro, are a stabilizing extension bolted onto the C-terminus. That tail is not decorative. Short peptides get chewed up quickly by peptidases, and the Pro-Gly-Pro cap increases resistance to enzymatic degradation, which is the same stabilization trick used in the sister peptide Semax.\u003C\u002Fp>\n\u003Cp>Selank was developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its molecular weight is approximately 751.9 g\u002Fmol, with the molecular formula C33H57N11O9 and CAS number 129623-01-4. It ships as a white lyophilized powder.\u003C\u002Fp>\n\u003Cp>Because the tuftsin fragment sits at the front of the molecule, Selank is often described as carrying two lineages at once: the immune-signaling heritage of tuftsin, and the regulatory-peptide behavior that the published research has characterized in the nervous system.\u003C\u002Fp>\n\u003Ch2>What has the research actually shown?\u003C\u002Fh2>\n\u003Cp>Here is where the discipline matters. The Selank literature is real, but it is concentrated in a specific set of research groups and model systems, and most of it is preclinical. The strongest and most mechanistically specific line of evidence sits in anxiety and GABA-system models.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>The GABA-system mechanism.\u003C\u002Fstrong> One of the most detailed molecular account comes from a 2018 review that examined how Selank produces its anti-anxiety activity in research models. The authors proposed that one of Selank’s mechanisms may involve subtype-selective, concentration-dependent allosteric modulation of GABA receptors, which is the same receptor system that classical benzodiazepines act on (\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F30255741\u002F\" target=\"_blank\" rel=\"noopener\">Vyunova et al., *Protein and Peptide Letters*, 2018\u003C\u002Fa>). “May involve” is the honest framing there; this is a proposed mechanism characterized in experimental systems, not a settled account.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Anxiolytic behavioral models.\u003C\u002Fstrong> In a rat model of unpredictable chronic mild stress, Selank was studied alongside diazepam, and the authors reported that its anxiolytic effect was comparable to that of classical benzodiazepine drugs, with a mechanism they suggested may overlap (\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F28280289\u002F\" target=\"_blank\" rel=\"noopener\">Kasian et al., *Behavioural Neurology*, 2017\u003C\u002Fa>). This is an animal-behavior assay, and the comparison is between compounds in that model.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>BDNF and neurotrophic signaling.\u003C\u002Fstrong> In outbred rats, Selank was studied for its effect on ethanol-induced memory impairment and on brain-derived neurotrophic factor (BDNF) content in the hippocampus and prefrontal cortex (\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F31625062\u002F\" target=\"_blank\" rel=\"noopener\">Kolik et al., *Bulletin of Experimental Biology and Medicine*, 2019\u003C\u002Fa>). BDNF is a protein that supports the growth and maintenance of neurons, and it turns up repeatedly across both the Selank and Semax literature.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Human neuroimaging.\u003C\u002Fstrong> One of the few human studies used resting-state functional MRI to examine how Selank and Semax affect whole-brain functional connectivity in 52 healthy participants, with the amygdala among the predefined regions of interest (\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32342318\u002F\" target=\"_blank\" rel=\"noopener\">Panikratova et al., *Doklady Biological Sciences*, 2020\u003C\u002Fa>). This is worth knowing about because most of the Selank evidence base is animal work; direct human data is comparatively thin.\u003C\u002Fp>\n\u003Cp>If you are designing a study, the takeaway is that the most consistently reported mechanistic finding is in the anxiolytic and GABA-system literature, the evidence concentrates around a specific group of Russian investigators, and the translation of these observations beyond those model systems is not fully characterized.\u003C\u002Fp>\n\u003Ch2>Selank at a glance\u003C\u002Fh2>\n\u003Ctable>\n\u003Cthead>\n\u003Ctr>\n\u003Cth>\u003Cstrong>Attribute\u003C\u002Fstrong>\u003C\u002Fth>\n\u003Cth>\u003Cstrong>Detail\u003C\u002Fstrong>\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>Sequence\u003C\u002Ftd>\n\u003Ctd>Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Class\u003C\u002Ftd>\n\u003Ctd>Synthetic heptapeptide, stabilized tuftsin analog\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Molecular weight\u003C\u002Ftd>\n\u003Ctd>~751.9 g\u002Fmol (per Velora product specifications)\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Molecular formula\u003C\u002Ftd>\n\u003Ctd>C33H57N11O9\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>CAS number\u003C\u002Ftd>\n\u003Ctd>129623-01-4\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Origin\u003C\u002Ftd>\n\u003Ctd>Institute of Molecular Genetics, Russia, 1990s\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Primary research areas\u003C\u002Ftd>\n\u003Ctd>Anxiolytic models, GABA-system research, BDNF\u002Fneurotrophic research, immunomodulation\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Regulatory status (Russia, Ukraine)\u003C\u002Ftd>\n\u003Ctd>Approved prescription medication (Selank brand, intranasal)\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Regulatory status (US, EU)\u003C\u002Ftd>\n\u003Ctd>Not approved; research use only\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Ch2>Reconstitution and concentration, in the units that matter\u003C\u002Fh2>\n\u003Cp>For a 10 mg vial, a common starting point used in laboratory practice is 2 mL of bacteriostatic water, which yields a 5 mg\u002FmL stock. Using Velora’s product-page molecular weight of 751.9 g\u002Fmol, that 5 mg\u002FmL stock corresponds to a molar concentration of approximately 6.65 mM. From there, cell-based assays that call for nanomolar-to-micromolar working concentrations will need serial dilution in an assay-appropriate buffer; a 6.65 mM stock diluted 1:1,000 lands at roughly 6.65 µM.\u003C\u002Fp>\n\u003Cp>Reconstitute the way you would any lyophilized peptide: add diluent slowly against the inner glass wall, swirl gently rather than shaking, and label the vial with the date and the final concentration in both mg\u002FmL and mM. Confirm the molecular weight on your specific batch Certificate of Analysis before you finalize the molar math, since that value drives every downstream dilution.\u003C\u002Fp>\n\u003Cp>For storage, follow standard peptide-chemistry practice: keep the lyophilized vial sealed at -20°C, protected from light, and refrigerate any reconstituted stock at 2 to 8°C. Velora has not published a specific reconstituted stability window for this product, so treat the usable timeframe as something to establish from your own protocol and the batch COA rather than a fixed shelf life.\u003C\u002Fp>\n\u003Ch2>Routes used in published research\u003C\u002Fh2>\n\u003Cp>Two administration routes dominate the published Selank research in animal models: intranasal and subcutaneous. The intranasal route features heavily in the Russian research literature, which is also why “selank nasal spray” shows up so often as a search term. For research purposes, the route used in any protocol is a study-design choice to be selected and validated against the peer-reviewed literature and institutional approvals. None of these routes is a translation to human or veterinary use, and the Velora product is not sold for any such purpose.\u003C\u002Fp>\n\u003Ch2>Selank and Semax: the sister-peptide question\u003C\u002Fh2>\n\u003Cp>Researchers almost always encounter Selank and Semax together, and it helps to keep the difference straight. Both are seven-amino-acid regulatory peptides that came out of the same Russian research institute, both carry the C-terminal Pro-Gly-Pro stabilization, and both are approved clinical drugs in Russia while remaining research-only in the West. The difference is lineage and research focus. Selank descends from tuftsin and is most studied in the anxiolytic and GABA-system literature. Semax descends from an ACTH (4-10) derived analogue and is most studied in the BDNF, neurotrophic-factor, and cerebrovascular literature. For a full treatment of the second peptide, see our Semax research reference.\u003C\u002Fp>\n\u003Cp>“When people ask me what to check first on a peptide like Selank, the answer is always the same: identity by mass spectrometry and purity by HPLC, on the specific batch. The sequence is short, and the chemistry is reproducible, but ‘reproducible’ only means anything if the COA confirms you actually have TKPRPGP at the purity the label claims. Everything downstream rests on that.”\u003C\u002Fp>\n\u003Cp>Clark Jones, PhD, Velora Research\u003C\u002Fp>\n\u003Ch2>Working with verified material\u003C\u002Fh2>\n\u003Cp>Velora Research supplies \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct\u002Fselank-10mg\u002F\">Selank peptide as a 10 mg lyophilized research compound\u003C\u002Fa> with a batch-specific third-party Certificate of Analysis. Each COA confirms identity by mass spectrometry and purity by HPLC at ≥99%, tied to the lot number on the vial. The same release protocol applies across the \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct-category\u002Fpeptides\u002F\">research peptide catalog\u003C\u002Fa>, and the \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fabout-us\u002F\">quality and testing process\u003C\u002Fa> is documented end to end. For a research-grade regulatory peptide with a literature base as group-specific as Selank’s, knowing exactly what is in the vial is the difference between a reproducible result and an unexplained one.\u003C\u002Fp>\n\u003Ch2>Frequently asked questions\u003C\u002Fh2>\n\u003Ch3>What are the documented Selank research findings?\u003C\u002Fh3>\n\u003Cp>Published preclinical and clinical literature has characterized Selank across several research areas: GABA-system signaling, anxiolytic behavioral models, BDNF and neurotrophic-factor expression, and immunomodulation derived from its tuftsin origin. These are areas of published research interest observed in experimental systems. They are not therapeutic claims, and they do not describe outcomes in people.\u003C\u002Fp>\n\u003Ch3>Is Selank FDA-approved?\u003C\u002Fh3>\n\u003Cp>No. Selank is not approved by the FDA or the EMA for any indication. It is approved as a prescription medication in Russia and Ukraine, but that regional product is distinct from a research-grade peptide, and Velora’s Selank is supplied strictly for laboratory research.\u003C\u002Fp>\n\u003Ch3>What is Selank’s molecular weight?\u003C\u002Fh3>\n\u003Cp>Approximately 751.9 g\u002Fmol, with the formula C33H57N11O9, per Velora’s product specifications. Confirm the value on your batch COA before calculating molar concentrations.\u003C\u002Fp>\n\u003Ch3>How does Selank differ from Semax?\u003C\u002Fh3>\n\u003Cp>Both are seven-amino-acid Russian-developed regulatory peptides sharing the Pro-Gly-Pro stabilization. Selank comes from tuftsin and is most studied in anxiolytic and GABA-system research; Semax comes from an ACTH (4-10) fragment and is most studied in BDNF and cerebrovascular research.\u003C\u002Fp>\n\u003Ch3>What is the sequence of Selank?\u003C\u002Fh3>\n\u003Cp>Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). The first four residues are tuftsin; the last three are a stabilizing extension.\u003C\u002Fp>\n\u003Ch2>Sources and further reading\u003C\u002Fh2>\n\u003Cul>\n\u003Cli>Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. \u003Cem>Protein and Peptide Letters\u003C\u002Fem>. 2018;25(10):914-923. \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F30255741\u002F\" target=\"_blank\" rel=\"noopener\">PubMed\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. \u003Cem>Behavioural Neurology\u003C\u002Fem>. 2017;2017:5091027. \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F28280289\u002F\" target=\"_blank\" rel=\"noopener\">PubMed\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Kolik LG, Nadorova AV, Antipova TA, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. \u003Cem>Bulletin of Experimental Biology and Medicine\u003C\u002Fem>. 2019;167(5):641-644. \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F31625062\u002F\" target=\"_blank\" rel=\"noopener\">PubMed\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. \u003Cem>Doklady Biological Sciences\u003C\u002Fem>. 2020;490(1):9-11. \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F32342318\u002F\" target=\"_blank\" rel=\"noopener\">PubMed\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003Cem>This article is provided for laboratory and scientific reference. Selank is a research compound, not an approved drug in the United States or European Union. The research-grade material Velora Research supplies is distinct from the Selank-brand pharmaceutical approved by regulators in Russia and Ukraine. Products sold by Velora Research are for in-vitro research use only and are not intended for human or veterinary use. Researchers are responsible for compliance with applicable laws and institutional protocols.\u003C\u002Fem>\u003Cbr \u002F>\n\u003Cscript type=\"application\u002Fld+json\">\n{\n  \"@context\": \"https:\u002F\u002Fschema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the documented Selank research findings?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Published preclinical and clinical literature has characterized Selank across several research areas, including GABA-system signaling, anxiolytic behavioral models, BDNF and neurotrophic-factor expression, and immunomodulation related to its tuftsin origin. These findings represent areas of scientific research and do not establish therapeutic benefits or outcomes in humans.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Selank FDA-approved?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"No. Selank is not approved by the FDA or the European Medicines Agency (EMA) for any indication. It is approved as a prescription medication in Russia and Ukraine. These regional products are distinct from research-grade peptides, and Velora's Selank is supplied strictly for laboratory research.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Selank's molecular weight?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Selank has an approximate molecular weight of 751.9 g\u002Fmol and a molecular formula of C33H57N11O9, according to Velora's product specifications. Confirm the molecular weight using the certificate of analysis (COA) for your specific batch before calculating molar concentrations.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How does Selank differ from Semax?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Selank and Semax are both seven-amino-acid Russian-developed regulatory peptides that share a Pro-Gly-Pro stabilization motif. Selank is derived from tuftsin and is primarily studied in anxiolytic and GABA-system research. Semax is derived from an ACTH (4-10) fragment and is primarily studied in BDNF-related and cerebrovascular research.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the sequence of Selank?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"The amino acid sequence of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). The first four amino acids correspond to tuftsin, while the final three amino acids form a stabilizing extension.\"\n      }\n    }\n  ]\n}\n\u003C\u002Fscript>\u003C\u002Fp>\n","Quick answer: Selank is a synthetic seven-amino-acid peptide built from the natural immunomodulatory tetrapeptide tuftsin, with a stabilizing tail added so it survives longer in solution. Most of the…","\u002Fblogs\u002Fselank-peptide-mechanism-research-reconstitution","2026-10-14T14:05:44",{"src":88,"alt":89,"width":16,"height":17},"https:\u002F\u002Fwp.veloraresearch.com\u002Fwp-content\u002Fuploads\u002F2026\u002F10\u002FSelank-Peptide-2.jpg","Selank Peptide",{"title":19,"description":91,"canonical":19,"ogTitle":19,"ogDescription":91,"ogImage":88,"robots":19},"Explore Selank peptide, including its proposed mechanisms, key research areas, and reconstitution reference for laboratory research and scientific study.","2026-10-13T13:42:52",{"id":23,"slug":24,"name":25,"firstName":25,"display":26,"credentials":27,"bio":28,"avatar":29,"avatar2x":30,"roles":94,"focusAreas":95,"expertise":96,"orcid":45,"linkedin":46,"editorialNote":47,"path":48},[32,33],[35,36,37,38],[40,41,37,42,43,44],[],{"id":99,"slug":100,"title":101,"content":102,"excerpt":103,"path":104,"modified":105,"featuredImage":106,"seo":109,"date":111,"author":112,"categories":116,"readingMinutes":78},43534,"tesamorelin-vs-sermorelin-vs-ipamorelin","Tesamorelin vs Sermorelin vs Ipamorelin: A Research Comparison of GHRH Analogs and GHRPs","\u003Cp>\u003Cstrong>Quick answer:\u003C\u002Fstrong> Sermorelin, tesamorelin, and ipamorelin are three short peptides that all end up in growth-hormone-axis research, but they don’t act through the same receptor. Sermorelin and tesamorelin are growth-hormone-releasing hormone (GHRH) analogs. Ipamorelin is a growth-hormone-releasing peptide (GHRP) that acts through the ghrelin receptor. Tesamorelin is the only one of the three that is FDA-approved, sold as Egrifta for HIV-associated lipodystrophy. Velora supplies all three as research compounds for in-vitro work.\u003C\u002Fp>\n\u003Ch2>Research use only: what this article is, and what it isn’t\u003C\u002Fh2>\n\u003Cp>This article is a mechanism-focused comparison of three growth-hormone-axis peptides, written for researchers selecting reference compounds for in-vitro or preclinical work. It is not medical advice, and it is not a prescribing or self-administration guide.\u003C\u002Fp>\n\u003Cp>Tesamorelin is FDA-approved as Egrifta (and Egrifta SV, a more concentrated formulation) for the specific indication of HIV-associated lipodystrophy in adult patients with excess abdominal fat. That approved product is a prescription medication supplied through controlled clinical channels. The tesamorelin Velora sells as a 10 mg research vial is a research-grade material for laboratory use, not the approved drug, and is not intended for human or veterinary use under any framing.\u003C\u002Fp>\n\u003Cp>Sermorelin and ipamorelin are not FDA-approved as drugs for any indication. (Sermorelin previously had an FDA-approved formulation, Geref, that was discontinued from the U.S. market in 2008; it is no longer an approved drug in the United States.) The Velora research-grade material for both peptides is supplied for in-vitro research only. Researchers handling any of these compounds are responsible for compliance with applicable law, including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331, § 355, § 360bbb-3), and institutional review requirements.\u003C\u002Fp>\n\u003Ch2>The mechanism that separates them\u003C\u002Fh2>\n\u003Cp>The primary mechanistic distinction to keep straight is that these three peptides act on two different receptors.\u003C\u002Fp>\n\u003Cp>GHRH (growth-hormone-releasing hormone) is the hypothalamic hormone that signals the anterior pituitary to release growth hormone. Sermorelin and tesamorelin are GHRH-receptor agonists. They act as agonists at the GHRH receptor by mimicking endogenous GHRH signaling.\u003C\u002Fp>\n\u003Cp>GHRPs (growth-hormone-releasing peptides) are a separate class that act on a different receptor entirely: the ghrelin receptor (GHSR-1a), which sits on the same pituitary cells. Ipamorelin is a selective GHRP. It is not a GHRH analog. The two classes can be studied separately or in combination because they engage independent pathways that converge on growth-hormone secretion.\u003C\u002Fp>\n\u003Ctable>\n\u003Cthead>\n\u003Ctr>\n\u003Cth>\u003Cstrong>Compound\u003C\u002Fstrong>\u003C\u002Fth>\n\u003Cth>\u003Cstrong>Class\u003C\u002Fstrong>\u003C\u002Fth>\n\u003Cth>\u003Cstrong>Receptor\u003C\u002Fstrong>\u003C\u002Fth>\n\u003Cth>\u003Cstrong>Sequence basis\u003C\u002Fstrong>\u003C\u002Fth>\n\u003Cth>\u003Cstrong>FDA status\u003C\u002Fstrong>\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>Sermorelin\u003C\u002Ftd>\n\u003Ctd>GHRH analog\u003C\u002Ftd>\n\u003Ctd>GHRH receptor\u003C\u002Ftd>\n\u003Ctd>Native GHRH 1-29\u003C\u002Ftd>\n\u003Ctd>Not approved (Geref discontinued 2008)\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Tesamorelin\u003C\u002Ftd>\n\u003Ctd>Stabilized GHRH analog\u003C\u002Ftd>\n\u003Ctd>GHRH receptor\u003C\u002Ftd>\n\u003Ctd>GHRH 1-44 with N-terminal trans-3-hexenoic acid modification\u003C\u002Ftd>\n\u003Ctd>Approved (Egrifta \u002F Egrifta SV, HIV lipodystrophy)\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Ipamorelin\u003C\u002Ftd>\n\u003Ctd>GHRP (selective)\u003C\u002Ftd>\n\u003Ctd>Ghrelin receptor (GHSR-1a)\u003C\u002Ftd>\n\u003Ctd>Synthetic pentapeptide\u003C\u002Ftd>\n\u003Ctd>Not approved\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Ch2>Sermorelin, in research terms\u003C\u002Fh2>\n\u003Cp>Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of native GHRH, which is the smallest fragment that retains full biological activity at the GHRH receptor. The molecular weight is approximately 3,358 daltons. Its half-life in circulation is short, on the order of 10 to 20 minutes, which is why historical clinical use relied on bedtime administration in pediatric growth-hormone studies, mimicking the natural nocturnal GHRH pulse.\u003C\u002Fp>\n\u003Cp>The published research base on sermorelin sits mostly in the pediatric endocrinology literature from the 1980s and 1990s, when it was used as a diagnostic and treatment tool for growth-hormone deficiency in children. The FDA-approved formulation Geref was withdrawn from the U.S. market in 2008 for commercial rather than safety reasons, and sermorelin has not been a U.S. approved drug since. For benchwork, sermorelin is the GHRH-receptor reference compound when you need a peptide that mirrors the native ligand sequence directly.\u003C\u002Fp>\n\u003Ch2>Tesamorelin, in research terms\u003C\u002Fh2>\n\u003Cp>Tesamorelin is the same GHRH backbone but engineered for stability. It uses the longer GHRH 1-44 sequence rather than the 1-29 fragment, and it has a trans-3-hexenoic acid modification on the N-terminus that significantly extends the half-life by resisting cleavage by dipeptidyl peptidase IV. The reported half-life is approximately 26 minutes in healthy adults, much longer than sermorelin’s. The molecular weight is approximately 5,135 daltons.\u003C\u002Fp>\n\u003Cp>Tesamorelin was approved by the FDA in 2010 as Egrifta for the specific indication of reduction in excess abdominal fat in HIV-infected patients with lipodystrophy. The pivotal Phase 3 data was published in \u003Cem>NEJM\u003C\u002Fem> in 2007 by Falutz and colleagues, reporting significant reductions in visceral adipose tissue and improvements in IGF-1 over 26 weeks at 2 mg subcutaneously daily (\u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa072375\" target=\"_blank\" rel=\"noopener\">Falutz et al., NEJM, 2007\u003C\u002Fa>).\u003C\u002Fp>\n\u003Cp>Because the approved use targets visceral adiposity specifically, tesamorelin is the GHRH analog that turns up most often in body-composition research literature. That research framing is distinct from the broader marketing context the compound shows up in elsewhere. For research use, tesamorelin is the comparator when the question is GHRH-receptor agonism with a usable in vivo half-life.\u003C\u002Fp>\n\u003Ch2>Ipamorelin, in research terms\u003C\u002Fh2>\n\u003Cp>Ipamorelin is a synthetic pentapeptide originally characterized by Raun and colleagues at Novo Nordisk in 1998 (\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F9849822\u002F\" target=\"_blank\" rel=\"noopener\">Kirsten Raun et al., 1998\u003C\u002Fa>).. Its distinguishing feature in the GHRP class is selectivity: it stimulates growth-hormone release through the ghrelin receptor with substantially less stimulation of cortisol, prolactin, and ACTH than earlier GHRPs like GHRP-6 caused. That selectivity is what makes it useful as a research reference compound for GHSR-1a pharmacology in isolation. The molecular weight is approximately 712 daltons.\u003C\u002Fp>\n\u003Cp>Because GHRPs and GHRH analogs act through independent receptors, ipamorelin is sometimes studied alongside a GHRH analog like sermorelin or tesamorelin to characterize convergent versus independent contributions to growth-hormone release. That combination research is what generates the recurring question of GHRH-and-GHRP “co-administration” in the literature.\u003C\u002Fp>\n\u003Ch2>Side-by-side comparison\u003C\u002Fh2>\n\u003Ctable>\n\u003Cthead>\n\u003Ctr>\n\u003Cth>****\u003C\u002Fth>\n\u003Cth>\u003Cstrong>Sermorelin\u003C\u002Fstrong>\u003C\u002Fth>\n\u003Cth>\u003Cstrong>Tesamorelin\u003C\u002Fstrong>\u003C\u002Fth>\n\u003Cth>\u003Cstrong>Ipamorelin\u003C\u002Fstrong>\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>Class\u003C\u002Ftd>\n\u003Ctd>GHRH analog\u003C\u002Ftd>\n\u003Ctd>GHRH analog (stabilized)\u003C\u002Ftd>\n\u003Ctd>GHRP (selective)\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Receptor\u003C\u002Ftd>\n\u003Ctd>GHRH-R\u003C\u002Ftd>\n\u003Ctd>GHRH-R\u003C\u002Ftd>\n\u003Ctd>Ghrelin receptor (GHSR-1a)\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Molecular weight\u003C\u002Ftd>\n\u003Ctd>~3,358 Da\u003C\u002Ftd>\n\u003Ctd>~5,135 Da\u003C\u002Ftd>\n\u003Ctd>~712 Da\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Half-life\u003C\u002Ftd>\n\u003Ctd>~10-20 min\u003C\u002Ftd>\n\u003Ctd>~26 min\u003C\u002Ftd>\n\u003Ctd>~2 hours (preclinical reports vary)\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Sequence\u003C\u002Ftd>\n\u003Ctd>GHRH 1-29\u003C\u002Ftd>\n\u003Ctd>GHRH 1-44 + N-terminal modification\u003C\u002Ftd>\n\u003Ctd>Aib-His-D-2-Nal-D-Phe-Lys-NH2\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>Selectivity profile\u003C\u002Ftd>\n\u003Ctd>GHRH-R selective\u003C\u002Ftd>\n\u003Ctd>GHRH-R selective\u003C\u002Ftd>\n\u003Ctd>GHSR-1a; minimal cortisol\u002Fprolactin\u002FACTH effect (per Raun 1998)\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>FDA status (US)\u003C\u002Ftd>\n\u003Ctd>Not approved (Geref withdrawn 2008)\u003C\u002Ftd>\n\u003Ctd>Approved (Egrifta \u002F Egrifta SV, HIV lipodystrophy)\u003C\u002Ftd>\n\u003Ctd>Not approved\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Cp>Two things this table is not telling you. First, it is a comparison of mechanism and pharmacology, not of clinical effect; clinical efficacy is established only for the one FDA-approved indication for tesamorelin and is not transferable to any other use. Second, the half-life values reported in the literature vary by route, by species, and by assay; the figures above are the ones most commonly cited in published reviews and should be confirmed in any specific source you cite.\u003C\u002Fp>\n\u003Ch2>Reconstitution math for a 10 mg vial of any of the three\u003C\u002Fh2>\n\u003Cp>The three peptides differ in molecular weight and somewhat in handling, but the reconstitution math follows the same template. Bacteriostatic water is the standard diluent for multi-access research vials; the 0.9% benzyl alcohol preserves the in-use window.\u003C\u002Fp>\n\u003Ctable>\n\u003Cthead>\n\u003Ctr>\n\u003Cth>\u003Cstrong>Vial mass\u003C\u002Fstrong>\u003C\u002Fth>\n\u003Cth>\u003Cstrong>BAC water volume\u003C\u002Fstrong>\u003C\u002Fth>\n\u003Cth>\u003Cstrong>Stock concentration (mg\u002FmL)\u003C\u002Fstrong>\u003C\u002Fth>\n\u003Cth>\u003Cstrong>Approximate molar concentration (mM)\u003C\u002Fstrong>\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>10 mg sermorelin\u003C\u002Ftd>\n\u003Ctd>2.0 mL\u003C\u002Ftd>\n\u003Ctd>5.0\u003C\u002Ftd>\n\u003Ctd>~1.49\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>10 mg tesamorelin\u003C\u002Ftd>\n\u003Ctd>2.0 mL\u003C\u002Ftd>\n\u003Ctd>5.0\u003C\u002Ftd>\n\u003Ctd>~0.97\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>10 mg ipamorelin\u003C\u002Ftd>\n\u003Ctd>2.0 mL\u003C\u002Ftd>\n\u003Ctd>5.0\u003C\u002Ftd>\n\u003Ctd>~7.02\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>10 mg of any\u003C\u002Ftd>\n\u003Ctd>1.0 mL\u003C\u002Ftd>\n\u003Ctd>10.0\u003C\u002Ftd>\n\u003Ctd>sermorelin ~2.98 \u002F tesamorelin ~1.95 \u002F ipamorelin ~14.05\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Cp>Note that for the same gravimetric concentration (mg\u002FmL), the molar concentrations differ substantially because ipamorelin is roughly five to seven times smaller than the GHRH analogs. For receptor-binding work, that difference is generally more relevant for receptor pharmacology experiments.\u003C\u002Fp>\n\u003Cp>“The pharmacology only translates if the material does. Mass spec for identity, HPLC for purity, Karl Fischer for water content, LAL for endotoxin. On tesamorelin in particular, the chemistry is more structurally complex than sermorelin because of the N-terminal modification, and a clean COA from a reputable third-party lab helps confirm the expected molecular identity.”\u003C\u002Fp>\n\u003Cp>Clark Jones, PhD, Velora Research\u003C\u002Fp>\n\u003Ch2>Working with verified material\u003C\u002Fh2>\n\u003Cp>Velora supplies all three peptides as research-grade material with batch-specific third-party Certificates of Analysis. The \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct\u002Ftesamorelin-10mg\u002F\">Tesamorelin 10 mg vial\u003C\u002Fa> is the one most often used in body-composition research, and its COA covers identity by mass spec, purity by HPLC at ≥99%, water content by Karl Fischer, and endotoxin by LAL. The same release protocol applies across the \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct-category\u002Fpeptides\u002F\">research peptide catalog\u003C\u002Fa>, and the \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fabout-us\u002F\">quality and testing process\u003C\u002Fa> is documented end to end.\u003C\u002Fp>\n\u003Cp>For research designs that compare a GHRH analog to a GHRP at matched receptor exposure, having all three peptides from a single vendor with consistent batch documentation improves reproducibility and documentation across comparative studies.\u003C\u002Fp>\n\u003Ch2>Frequently asked questions\u003C\u002Fh2>\n\u003Ch3>Is tesamorelin the same thing as Egrifta?\u003C\u002Fh3>\n\u003Cp>The molecule is the same. The product context is not. Egrifta and Egrifta SV are the FDA-approved drug formulations manufactured for prescription use in HIV-associated lipodystrophy. The tesamorelin Velora sells is research-grade material supplied for in-vitro work and is not the approved drug.\u003C\u002Fp>\n\u003Ch3>Is sermorelin FDA-approved in the United States?\u003C\u002Fh3>\n\u003Cp>Not currently. The approved formulation Geref was discontinued from the U.S. market in 2008. Sermorelin is not an approved drug in the United States today.\u003C\u002Fp>\n\u003Ch3>Is ipamorelin FDA-approved?\u003C\u002Fh3>\n\u003Cp>No. Ipamorelin is not approved by the FDA or any other national regulator for any indication. It is supplied as a research compound only.\u003C\u002Fp>\n\u003Ch3>What makes ipamorelin “selective” among GHRPs?\u003C\u002Fh3>\n\u003Cp>Compared with earlier-generation GHRPs like GHRP-6, ipamorelin’s reported pharmacology shows substantially less effect on cortisol, prolactin, and ACTH release at doses that produce growth-hormone release, per the original characterization by Raun and colleagues in 1998. That selectivity is what makes it useful as a research reference compound for ghrelin-receptor pharmacology in isolation.\u003C\u002Fp>\n\u003Ch3>Why are GHRH analogs and GHRPs studied together?\u003C\u002Fh3>\n\u003Cp>Because they act through independent receptors that converge on the same pituitary somatotrophs. Combining them in a research design lets investigators ask whether the two pathways contribute additively or synergistically to growth-hormone release.\u003C\u002Fp>\n\u003Ch3>Which one shows up in body-composition research?\u003C\u002Fh3>\n\u003Cp>Tesamorelin, most commonly, because of its FDA-approved indication for visceral fat reduction in HIV lipodystrophy. The Egrifta clinical literature is the largest body of human data on any of these three compounds for body-composition endpoints. That literature applies to the approved indication and population, and it should not be extrapolated to other research framings without explicit study evidence.\u003C\u002Fp>\n\u003Ch2>Sources and further reading\u003C\u002Fh2>\n\u003Cul>\n\u003Cli>Falutz J, Allas S, Blot K, et al. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. \u003Cem>NEJM\u003C\u002Fem>. 2007. \u003Ca href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa072375\" target=\"_blank\" rel=\"noopener\">Full text\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. \u003Cem>European Journal of Endocrinology\u003C\u002Fem>. 1998. \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F9849822\u002F\" target=\"_blank\" rel=\"noopener\">Full text Full Text\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. \u003Cem>JAMA\u003C\u002Fem>. 2014. \u003Ca href=\"https:\u002F\u002Fjamanetwork.com\u002Fjournals\u002Fjama\u002Ffullarticle\u002F1889139\" target=\"_blank\" rel=\"noopener\">Abstract\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>U.S. FDA. Egrifta (tesamorelin for injection) Prescribing Information. \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2014\u002F022505s011lbl.pdf\" target=\"_blank\" rel=\"noopener\">FDA label database\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003Cem>This article is provided for laboratory and scientific reference. Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy; that approved product is a prescription drug and is not the research-grade material Velora supplies. Sermorelin and ipamorelin are not FDA-approved for any indication. Products sold by Velora Research are for in-vitro research use only and are not intended for human or veterinary use. Researchers are responsible for compliance with applicable laws and institutional protocols.\u003C\u002Fem>\u003Cbr \u002F>\n\u003Cscript type=\"application\u002Fld+json\">\n{\n  \"@context\": \"https:\u002F\u002Fschema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is tesamorelin the same thing as Egrifta?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"The molecule is the same, but the product context is different. Egrifta and Egrifta SV are FDA-approved prescription formulations of tesamorelin for HIV-associated lipodystrophy. Research-grade tesamorelin supplied by Velora is intended for in-vitro research and is not the FDA-approved drug.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is sermorelin FDA-approved in the United States?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"No. The sermorelin formulation Geref was discontinued from the U.S. market in 2008. Sermorelin is not currently an FDA-approved drug in the United States.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is ipamorelin FDA-approved?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"No. Ipamorelin is not FDA-approved for any indication in the United States. It is supplied as a research compound and is not an approved medication.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What makes ipamorelin selective among GHRPs?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Compared with earlier-generation growth hormone-releasing peptides such as GHRP-6, ipamorelin has been reported to produce less effect on cortisol, prolactin, and ACTH release at doses that stimulate growth hormone release. This selectivity, described in the original characterization by Raun and colleagues in 1998, makes ipamorelin useful as a research reference compound for studying ghrelin-receptor pharmacology.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Why are GHRH analogs and GHRPs studied together?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"GHRH analogs and growth hormone-releasing peptides (GHRPs) act through independent receptors that converge on pituitary somatotrophs. Studying them together allows researchers to investigate whether these pathways contribute additively or synergistically to growth hormone release.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Which one shows up in body-composition research?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Tesamorelin is the most prominent of these three compounds in body-composition research because it has an FDA-approved indication for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. The Egrifta clinical literature provides substantial human evidence for this specific indication and population, but those findings should not be extrapolated to other uses without supporting study evidence.\"\n      }\n    }\n  ]\n}\n\u003C\u002Fscript>\u003C\u002Fp>\n","Quick answer: Sermorelin, tesamorelin, and ipamorelin are three short peptides that all end up in growth-hormone-axis research, but they don’t act through the same receptor. Sermorelin and…","\u002Fblogs\u002Ftesamorelin-vs-sermorelin-vs-ipamorelin","2026-10-14T14:06:35",{"src":107,"alt":108,"width":16,"height":17},"https:\u002F\u002Fwp.veloraresearch.com\u002Fwp-content\u002Fuploads\u002F2026\u002F10\u002FTesamorelin-vs-Sermorelin-vs-Ipamorelin.png","Tesamorelin vs Sermorelin vs Ipamorelin",{"title":19,"description":110,"canonical":19,"ogTitle":19,"ogDescription":110,"ogImage":107,"robots":19},"Compare tesamorelin vs. sermorelin vs. ipamorelin, including their mechanisms, FDA approval status, and research applications.","2026-10-10T13:48:49",{"id":23,"slug":24,"name":25,"firstName":25,"display":26,"credentials":27,"bio":28,"avatar":29,"avatar2x":30,"roles":113,"focusAreas":114,"expertise":115,"orcid":45,"linkedin":46,"editorialNote":47,"path":48},[32,33],[35,36,37,38],[40,41,37,42,43,44],[117],{"name":51,"slug":52},{"id":119,"slug":120,"title":121,"content":122,"excerpt":123,"path":124,"modified":125,"featuredImage":126,"seo":128,"date":131,"author":132,"categories":136,"readingMinutes":138},43251,"melanotan-2-research-reference-melanocortin-peptide","Melanotan 2: A Research Reference on the Melanocortin Peptide","\u003Cp>\u003Cstrong>Quick answer:\u003C\u002Fstrong> Melanotan 2 (MT-2) is a synthetic cyclic peptide that acts as a broad agonist of melanocortin receptors, the receptor family involved in pigmentation and several other pathways. It is not approved for any use by any regulator, a status worth stating up front. In research it is studied for melanocortin-receptor pharmacology and pigmentation biology. Velora supplies it as a research compound for in vitro, ex vivo, and in silico work only.\u003C\u002Fp>\n\u003Ch2>Research use only: what this article is, and what it isn’t\u003C\u002Fh2>\n\u003Cp>This is a compound-education reference on Melanotan 2 for researchers. It explains the peptide’s structure, its receptor targets, and its regulatory status. It is not medical advice, not a tanning or self-administration guide, and not a document about any human or veterinary use.\u003C\u002Fp>\n\u003Cp>Melanotan 2 is not approved by the U.S. Food and Drug Administration, the European Medicines Agency, or any other regulator for any indication or use. Velora Research supplies it as research-grade material sold strictly for in vitro, ex vivo, and in silico laboratory research, not for human consumption, veterinary use, in vivo use in any species, or any personal, cosmetic, or tanning application. Every effect described below comes from published research and is reported here for research orientation only. Researchers are responsible for compliance with applicable law, including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331, § 355, § 360bbb-3), and institutional review requirements.\u003C\u002Fp>\n\u003Ch2>What Melanotan 2 is\u003C\u002Fh2>\n\u003Cp>Melanotan 2 is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH), the natural melanocortin peptide. Its molecular weight is approximately 1024.18 g\u002Fmol, with the formula C50H69N15O9 and CAS number 121062-08-6. The cyclic structure is deliberate: it makes the peptide more resistant to breakdown and more potent at its receptors than the linear natural hormone, which is why it became a research tool in melanocortin pharmacology in the first place. Its development history, alongside the MC1R-selective Melanotan 1, is described by Hadley and colleagues (\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F9760697\u002F\" target=\"_blank\" rel=\"noopener\">Hadley et al., *Pharmaceutical Biotechnology*, 1998\u003C\u002Fa>).\u003C\u002Fp>\n\u003Ch2>How it works: melanocortin receptors\u003C\u002Fh2>\n\u003Cp>The melanocortin system is a family of five receptors, MC1R through MC5R, that sit in different tissues and govern different processes, from pigmentation (MC1R) to appetite and other central pathways (MC4R). The defining feature of Melanotan 2, and the one that separates it from Melanotan 1, is breadth: MT-2 is a non-selective agonist that activates melanocortin receptors broadly, whereas MT-1 (afamelanotide) is comparatively MC1R-selective. The melanocortin peptides and their receptor pharmacology are reviewed by Hadley and Dorr (\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F16412534\u002F\" target=\"_blank\" rel=\"noopener\">Hadley & Dorr, *Peptides*, 2006\u003C\u002Fa>).\u003C\u002Fp>\n\u003Cp>That broad receptor activity is central to how MT-2 is studied and also to its reported side-effect profile in the literature, which is wider than a receptor-selective compound’s would be. As with all of this, the findings describe research and experimental systems, not outcomes anyone should expect, and MT-2’s unapproved status means it has not been through the safety evaluation an approved drug undergoes.\u003C\u002Fp>\n\u003Ch2>A note on Melanotan 1 and afamelanotide\u003C\u002Fh2>\n\u003Cp>The comparison to Melanotan 1 is where regulatory accuracy matters. Melanotan 1 is afamelanotide, which is FDA-approved under the brand name Scenesse for a specific rare condition (erythropoietic protoporphyria), a use established in published clinical research (\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26132941\u002F\" target=\"_blank\" rel=\"noopener\">Langendonk et al., *New England Journal of Medicine*, 2015\u003C\u002Fa>). Melanotan 2 has no such approval. Velora’s research-grade Melanotan 1 is likewise not the approved drug. For the full side-by-side, see our Melanotan 1 vs Melanotan 2 comparison.\u003C\u002Fp>\n\u003Ch2>Reconstitution and concentration\u003C\u002Fh2>\n\u003Cp>The information here is general laboratory-handling context, not a use protocol. Follow your institution’s validated procedures and the product documentation for any specific step. Melanotan 2 ships as a lyophilized powder in a 10 mg vial. The table gives molar concentrations at common gravimetric concentrations, using the molecular weight of 1024.18 g\u002Fmol.\u003C\u002Fp>\n\u003Cdiv style=\"max-width: 100%; overflow-x: auto; margin: 30px 0; border-radius: 16px; box-shadow: 0 12px 30px rgba(0,0,0,0.10);\">\n\u003Ctable style=\"width: 100%; min-width: 600px; border-collapse: collapse; background: #ffffff; border-radius: 16px; overflow: hidden; font-family: Arial, Helvetica, sans-serif; color: #1f2937;\">\n\u003Cthead>\n\u003Ctr style=\"background: #111827; color: #ffffff;\">\n\u003Cth style=\"padding: 16px 18px; text-align: left; font-size: 15px; font-weight: 600; border-right: 1px solid rgba(255,255,255,0.12);\">BAC Water Volume\u003C\u002Fth>\n\u003Cth style=\"padding: 16px 18px; text-align: left; font-size: 15px; font-weight: 600; border-right: 1px solid rgba(255,255,255,0.12);\">Concentration (mg\u002FmL)\u003C\u002Fth>\n\u003Cth style=\"padding: 16px 18px; text-align: left; font-size: 15px; font-weight: 600;\">Molar Concentration (mM)\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr style=\"background: #ffffff;\">\n\u003Ctd style=\"padding: 15px 18px; font-size: 15px; border-bottom: 1px solid #e5e7eb;\">1.0 mL\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 18px; font-size: 15px; border-bottom: 1px solid #e5e7eb;\">10.0\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 18px; font-size: 15px; border-bottom: 1px solid #e5e7eb;\">~9.76\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr style=\"background: #f9fafb;\">\n\u003Ctd style=\"padding: 15px 18px; font-size: 15px; border-bottom: 1px solid #e5e7eb;\">2.0 mL\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 18px; font-size: 15px; border-bottom: 1px solid #e5e7eb;\">5.0\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 18px; font-size: 15px; border-bottom: 1px solid #e5e7eb;\">~4.88\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr style=\"background: #ffffff;\">\n\u003Ctd style=\"padding: 15px 18px; font-size: 15px;\">3.0 mL\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 18px; font-size: 15px;\">~3.33\u003C\u002Ftd>\n\u003Ctd style=\"padding: 15px 18px; font-size: 15px;\">~3.25\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003C\u002Fdiv>\n\u003Cp>Reconstitute with bacteriostatic water using the standard slow-stream technique against the inner glass wall, swirling gently rather than shaking, and work in µL and molar units for receptor-binding assays. Confirm the molecular weight and purity against the batch Certificate of Analysis before finalizing any dilution.\u003C\u002Fp>\n\u003Ch2>Storage\u003C\u002Fh2>\n\u003Cp>Keep the lyophilized vial sealed at -20°C, protected from light, and let it equilibrate to room temperature before opening. Once reconstituted, refrigerate the working stock at 2 to 8°C, protect it from light, and aliquot into single-use portions to avoid freeze-thaw cycles. These are established peptide-chemistry conventions; the broader logic is in the peptide storage guide. Velora has not published a reconstituted stability window for this compound, so take the usable timeframe from your protocol and the batch COA.\u003C\u002Fp>\n\u003Cblockquote>\u003Cp>\u003Cem>“Melanotan 2 is a good example of why receptor selectivity belongs in the first paragraph of any compound summary. A broad melanocortin agonist behaves differently in an assay than an MC1R-selective one, so the first thing I confirm is that I have the molecule I think I have, by mass spectrometry, at the purity the label claims. And I keep the regulatory status front of mind: MT-2 is not approved, which is exactly why careful, well-documented research handling matters.”\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cem>Clark Jones, PhD, Velora Research\u003C\u002Fem>\u003C\u002Fp>\u003C\u002Fblockquote>\n\u003Ch2>Working with verified material\u003C\u002Fh2>\n\u003Cp>Velora Research supplies \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct\u002Fmelanotan-2-10mg\u002F\">Melanotan 2\u003C\u002Fa> as a 10 mg lyophilized vial with a batch-specific third-party Certificate of Analysis reporting identity by mass spectrometry and purity by HPLC, published through the \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fcoas\u002F\">Certificates of Analysis\u003C\u002Fa> hub. The same release protocol applies across the \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct-category\u002Fpeptides\u002F\">research peptide catalog\u003C\u002Fa>, and the \u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fabout-us\u002F\">quality and testing process\u003C\u002Fa> is documented end to end. For melanocortin-receptor research, starting from verified, correctly identified material is what keeps a result interpretable.\u003C\u002Fp>\n\u003Ch2>Frequently asked questions\u003C\u002Fh2>\n\u003Ch3>1. What is Melanotan 2?\u003C\u002Fh3>\n\u003Cp>Melanotan 2 (MT-2) is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone that acts as a broad agonist of melanocortin receptors. Velora supplies it for in vitro, ex vivo, and in silico research use only.\u003C\u002Fp>\n\u003Ch3>2. How does Melanotan 2 work?\u003C\u002Fh3>\n\u003Cp>It activates melanocortin receptors (MC1R through MC5R) broadly, rather than selectively. That breadth distinguishes it from the more MC1R-selective Melanotan 1 and is central to how it is studied.\u003C\u002Fp>\n\u003Ch3>3. What is Melanotan 2’s molecular weight?\u003C\u002Fh3>\n\u003Cp>Approximately 1024.18 g\u002Fmol, formula C50H69N15O9, CAS 121062-08-6. Confirm the value on the batch COA before calculating molar concentrations.\u003C\u002Fp>\n\u003Ch3>4. Is Melanotan 2 FDA-approved?\u003C\u002Fh3>\n\u003Cp>No. Melanotan 2 is not approved by the FDA or any other regulator for any use. It is research-grade material for in vitro, ex vivo, and in silico laboratory use only, not for human or veterinary use.\u003C\u002Fp>\n\u003Ch3>How is Melanotan 2 different from Melanotan 1?\u003C\u002Fh3>\n\u003Cp>Melanotan 2 is a broad melanocortin-receptor agonist; Melanotan 1 (afamelanotide) is comparatively MC1R-selective and is FDA-approved as Scenesse for a specific rare condition. Velora’s research-grade materials are not the approved drug.\u003C\u002Fp>\n\u003Ch2>Sources and further reading\u003C\u002Fh2>\n\u003Cul>\n\u003Cli>Hadley ME, Hruby VJ, Blanchard J, et al. Discovery and development of novel melanogenic drugs. Melanotan-I and -II. \u003Cem>Pharmaceutical Biotechnology\u003C\u002Fem>. 1998;11:575-595. \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F9760697\u002F\" target=\"_blank\" rel=\"noopener\">PubMed\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. \u003Cem>Peptides\u003C\u002Fem>. 2006;27(4):921-930. \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F16412534\u002F\" target=\"_blank\" rel=\"noopener\">PubMed\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. \u003Cem>New England Journal of Medicine\u003C\u002Fem>. 2015;373(1):48-59. \u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F26132941\u002F\" target=\"_blank\" rel=\"noopener\">PubMed\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003Cem>This article is provided for laboratory and scientific reference. Melanotan 2 is an unapproved research compound. Products sold by Velora Research are for in-vitro, ex-vivo, and in-silico research use only and are not intended for human use, veterinary use, or in vivo use in any species. Researchers are responsible for compliance with applicable laws and institutional protocols.\u003C\u002Fem>\u003Cbr \u002F>\n\u003Cscript type=\"application\u002Fld+json\">\n{\n  \"@context\": \"https:\u002F\u002Fschema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Melanotan 2?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Melanotan 2 (MT-2) is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone that acts as a broad agonist of melanocortin receptors. Velora supplies it for in vitro, ex vivo, and in silico research use only.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How does Melanotan 2 work?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"It activates melanocortin receptors (MC1R through MC5R) broadly, rather than selectively. That breadth distinguishes it from the more MC1R-selective Melanotan 1 and is central to how it is studied.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Melanotan 2's molecular weight?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Approximately 1024.18 g\u002Fmol, formula C50H69N15O9, CAS 121062-08-6. Confirm the value on the batch COA before calculating molar concentrations.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Melanotan 2 FDA-approved?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"No. Melanotan 2 is not approved by the FDA or any other regulator for any use. It is research-grade material for in vitro, ex vivo, and in silico laboratory use only, not for human or veterinary use.\"\n      }\n    }\n  ]\n}\n\u003C\u002Fscript>\u003C\u002Fp>\n","Quick answer: Melanotan 2 (MT-2) is a synthetic cyclic peptide that acts as a broad agonist of melanocortin receptors, the receptor family involved in pigmentation and several other pathways. It is…","\u002Fblogs\u002Fmelanotan-2-research-reference-melanocortin-peptide","2026-10-14T14:07:12",{"src":127,"alt":121,"width":16,"height":17},"https:\u002F\u002Fwp.veloraresearch.com\u002Fwp-content\u002Fuploads\u002F2026\u002F09\u002FMelanotan-2-1.jpg",{"title":129,"description":130,"canonical":19,"ogTitle":129,"ogDescription":130,"ogImage":127,"robots":19},"Melanotan 2: Melanocortin Peptide Research Reference","Explore Melanotan 2 research, including its melanocortin activity, scientific background, mechanisms, and current research considerations.","2026-10-02T05:01:30",{"id":23,"slug":24,"name":25,"firstName":25,"display":26,"credentials":27,"bio":28,"avatar":29,"avatar2x":30,"roles":133,"focusAreas":134,"expertise":135,"orcid":45,"linkedin":46,"editorialNote":47,"path":48},[32,33],[35,36,37,38],[40,41,37,42,43,44],[137],{"name":51,"slug":52},5,23,6]